Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill and CFO Amy Parison. The company emphasized a platform centered on intravenous delivery of CRISPR components using lipid nanoparticles (LNPs), with a focus on making targeted, non-coding DNA edits [...]
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401
